louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01455987: Osteochondritis Dissecans of the Knee
Official title: Outcome of the Knee Osteochonditis Dissecans Patiets in Kuopio University Hospital (1990-2009): A Retropective Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteochondritis Dissecans
Juvenile Osteochondritis Dissecans
Keywords: Osteochondritis dissecans
Juvenile osteochondritis dissecans
Knee
Osteochondral
Outcome
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2011-10-20
Enrollment: 265
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who have been treated in Kuopio University Hospital (KUH) district for osteochondritis dissecans of the knee between 1.1.1990 and 31.12.2009.

Brief summary: Osteochondritis dissecans is a relatively common...


Eligibility criteria: Inclusion Criteria:

* Osteochondritis dissecans diagnosis code (ICD-8 to -10) in the medical records of KUH
* Knee OCD verified from the medical records

Exclusion Criteria:

-Any other medical condition

Primary outcomes:
measure: Knee pain measured by NRS (numeric rating scale, 0-10)
timeFrame: At the time of recruiting, which is an avarage calculated from all participiants enrolled for this study (estimated avarage follow-up 12-16 years).
Secondary outcomes:
measure: Lysholm Knee Score and Knee Injury and Osteoarthritis Outcome Score (KOOS)
timeFrame: At the time of recruiting, which is an avarage calculated from all participiants enrolled for this study (estimated avarage follow-up 12-16 years).
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01801787: Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia
Official title: The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Auditory Verbal Hallucinations
Schizophrenia
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2013-03-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current study investigates the basic principles that underlie the efficacy of transcranial direct current stimulation for chronic auditory verbal hallucinations in schizophrenia in a multimodal design.


Eligibility criteria: Inclusion Criteria:

* diagnosis of schizophrenia
* chronic auditory verbal hallucinations
* right-handed

Exclusion Criteria:

* drug abuse other than nicotine
* severe cognitive deficits
* severe medical conditions
* severe neurological disorders
* severe microangiopathy
* history of electroconvulsive therapy
* pregnancy or lactation

Primary outcomes:
measure: Change of Auditory Hallucination Rating Scale score
timeFrame: baseline; 3 days after intervention; 3 months after intervention
Secondary outcomes:
measure: Positive And Negative Syndrome Scale
timeFrame: baseline; 3 days after intervention; 3 months after intervention
Other outcomes:
measure: N1 suppression during talking and listening
timeFrame: baseline; 3 days after intervention
measure: Diffusion Tensor Imaging: Fractional anisotropy of longitudinal superior fascicle and arcuate fascicle
timeFrame: baseline; 3 days after intervention
measure: Default Mode Network connectivity
timeFrame: baseline; 3 days after intervention
Locations:
city: Berlin
country: Germany
facility: Charité University Medicine
city: Berlin
country: Germany
facility: Charité University Medicine
Study officials:
affiliation: Department of Neurology, Charité University Medicine Berlin
name: Robert Lindenberg, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Psychiatry, Charité University Medicine Berlin
name: Andres H. Neuhaus, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04885387: X-ray-free Protocol for Pectus Deformities Based on Magnetic Resonance 1 Imaging and a Low-cost Portable Three-dimensional Scanning Device
Official title: X-ray-free Protocol for Pectus Deformities Based on Magnetic Resonance 1 Imaging and a Low-cost Portable Three-dimensional Scanning Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pectus Deformity
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2021-05-13
Enrollment: 11
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Pectus excavatum (PE) and pectus carinatum (PC) are the most frequent chest wall deformities in humans. They are usually clinically recognized in early childhood or adolescence, with aggravation during the pubertal growth spurt. PE is a depression of the anterior chest wall, most frequently involving the lower sternum.

In this study we use simultaneously compared chest CT, MRI, and 3D scanning fro both PE and PC assessment .

The aim of this study is to compare a standard protocol using chest CT to a non-irradiant protocol with 3D scanning and MRI.

The primary endpoint was to assess the inter observer concordance and the correlation between the HI (Haller Index) evaluated with MRI and the EHI (External Haller index) evaluated with 3D scanning. The secondary endpoints were to assess the concordance with chest CT the variation of the HI evaluated in inspiration and expiration with MRI and also the correction index (CI) between chest CT and MRI in the PE group, .


Eligibility criteria: Inclusion Criteria:

* children (\< 18 years of age)
* with a pectus deformity
* recent (within the past month) chest CT, cardiothoracic MRI, and 3D scanning data were available.

Exclusion Criteria:

-

Primary outcomes:
measure: To compare a standard protocol using chest CT to a non-irradiant protocol involving a low-cost portable three-dimensional scanner and MRI for all pectus deformities based on the Haller index (HI)
timeFrame: At 12 month
Secondary outcomes:
measure: To compare the Haller Index measured with CT and the HI measured with low-cost portable three-dimensional scanner
timeFrame: At 12 month
measure: To compare the Haller Index measured with CT and the HI measured with MRI
timeFrame: At 12 month
Other outcomes:
Locations:
city: Limoges
country: France
facility: Service de chirurgie infantile
Study officials:
References:
Clinical trial NCT05531487: A 14-item Questionnaire Regarding Career Preferences Among Chinese Medical Undergraduate Students.
Official title: MC-career Choice Questionnaire for Exploring Insights Regarding the Motivations of Chinese Medical Students.
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Career Burnout
Student Burnout
Keywords: career choice
medical students
Lead sponsor: Shengjing Hospital
Sponsor class: OTHER
First posted: 2022-09-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A cross-sectional survey was supposed to be conducted. Participants from eight fourth-year student classes who were studying clinical medicine were enrolled.

Brief summary: This survey was performed as part of a career choice research program for undergraduate medical students. All students received a QR code link to the survey as part of their course work.

Detailed description: This survey was performed as part of a career choice research program for undergraduate medical students. All students received a QR code link to the survey as part of their course work, although participation was voluntary and anonymous. All participants received verbal and online explanations of the questionnaire and were informed that informed consent would be assumed if they completed and submitted the questionnaire. The questionnaire was administered, and data were collected using a free online tool.

Eligibility criteria: Inclusion Criteria:

* Participants from several four-year student classes medical students were enrolled.

Exclusion Criteria:

* Students who did not complete or declined to complete the questionnaire.

Primary outcomes:
measure: Questionnaire Results
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Shenjing Hospital of CHINA MEDICAL UNIVERSITY
state: Liaoning
Study officials:
affiliation: Shengjing Hospital
name: DONG JIA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02750787: Use of a Peptide-based Formula in an Adult Population
Official title: An Evaluation of the Use of a Peptide-based Formula in an Adult Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malabsorption
Lead sponsor: Abbott Nutrition
Sponsor class: INDUSTRY
First posted: 2016-04-26
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The study is designed to observe the use of a peptide-based oral nutrition supplement in adults with chronic malabsorption or maldigestion who require supplemental nutrition as assessed by a clinician.


Eligibility criteria: Inclusion Criteria:

* Subject is ≥ 18 years of age.
* Subject has chronic malabsorption or maldigestion.
* Subject requires supplemental nutrition as assessed by a clinician.
* Subject agrees to consume 2 servings of the study product a day for at least 16 consecutive days during Treatment period.

Exclusion Criteria:

* Subject is currently taking or has taken antibiotics within 2 weeks prior to enrollment in the study.
* Subject has current active malignant disease or was treated within the last 6 months for cancer.
* Subject has a history of diabetes mellitus.
* Subject is pregnant as demonstrated by a urine pregnancy test.
* Subject has severe auto immune disease and is on immuno-modulating therapy.
* Subject has a history of allergy to any of the ingredients in the study product.
* Subject has active HIV.
* Subject has a known aversion to flavor of product being tested.
* Subject has known dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder, or any other psychological condition that may interfere with study product consumption.
* Subject has an obstruction of the gastrointestinal tract precluding ingestion or absorption of the study product.
* Subject is taking part in another non-Sponsor approved clinical trial.

Primary outcomes:
measure: Study Product Consumption
timeFrame: Day 1 to Day 23
Secondary outcomes:
measure: Body Mass Index
timeFrame: Change from Screening to Day 23
measure: Medication Use
timeFrame: Screening to Study Day 23
measure: Adverse Events
timeFrame: Screening to Day 25
Other outcomes:
Locations:
city: Winnipeg
country: Canada
facility: St. Boniface Hospital
state: Manitoba
Study officials:
affiliation: Abbott Nutrition
name: Jeffrey L Nelson, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02338687: Low Dose Calcium to Prevent Preeclampsia
Official title: Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pre-Eclampsia
Hypertension, Pregnancy-Induced
Dietary Calcium Deficiency
Keywords: Calcium
Dietary supplements
Hypertension, Pregnancy-Induced
Pre-Eclampsia
Nutritional education
Diet therapy
Diet records
Hospitalization
Maternal mortality
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
Collaborators: name: PPSUS (Programa Pesquisa para o SUS: gestão compartilhada em saúde)
name: FAPEAM (Fundação de Amparo a Pesquisa do Estado do Amazonas)
name: Universidade Federal do Amazonas
First posted: 2015-01-14
Enrollment: 1040
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: cluster randomized
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess, in pregnant women with calcium-poor diets, what is the effectiveness of low-dose (500 mg/day) calcium supplements associated with an educational intervention, compared to the educational intervention alone, in the prevention of preeclampsia and hypertensive disorders during pregnancy.


Eligibility criteria: Inclusion Criteria:

* Capacity to understand verbal and visual instructions
* Gestational age 16 - 20 weeks
* Live fetus

Exclusion Criteria:

* Hyperparathyroidism or other contra-indication to calcium supplementation
* Gastrointestinal diseases or conditions that may interfere with calcium absorption (e.g. bariatric surgery, cancer, chronic colitis)
* Use of medications that may interfere with calcium absorption (e.g. corticosteroids, thiazides, thyroid hormones)
* Women already taking calcium supplements or daily antacids at recruitment

Primary outcomes:
measure: Preeclampsia
timeFrame: at 20-40 weeks of pregnancy
measure: Hypertensive disorders of pregnancy
timeFrame: at 20-40 weeks of pregnancy
Secondary outcomes:
measure: Mean change in dietary calcium intake
timeFrame: at 30-36 weeks of pregnancy
measure: Hospital admission due to hypertension
timeFrame: at 20-40 weeks of pregnancy
measure: Severe maternal morbidity
timeFrame: at 20-40 weeks of pregnancy
measure: Maternal mortality
timeFrame: starting at 20 weeks up to hospital discharge
measure: Gastrointestinal side effects of calcium
timeFrame: at 20-40 weeks of pregnancy
measure: Maternal admission to Intensive Care Unit
timeFrame: at 20-40 weeks of pregnancy
measure: Admission to Neonatal Intensive Care Unit
timeFrame: from delivery to infant discharge
measure: Preterm birth
timeFrame: at 20-36 weeks
measure: Low birth weight
timeFrame: at 20-40 weeks
measure: Small for gestational age infant
timeFrame: at 20-40 weeks
Other outcomes:
Locations:
city: Manaus
country: Brazil
facility: Universidade Federal do Amazonas
state: Amazonas
Study officials:
affiliation: Sao Paulo Federal University
name: Maria Regina Torloni, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04263987: A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Official title: A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Benign Prostatic Hyperplasia
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2020-02-11
Enrollment: 60
Sex: MALE
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses Pulse laser system provide for improved energy delivery which may decrease blood loss and operative time. We seek to evaluate Moses technology for enucleation of the prostate in the setting of BPH.

Detailed description: This is a single-center, prospective, double-blinded, randomized controlled trial comparing MOLEP to HOLEP. Inclusion criteria included all symptomatic BPH patients desiring enucleation with prostate sizes \> 80ccs based on cross-sectional imaging. Patients are randomized in a 1:1 fashion and the study is powered to evaluate for a difference in operative time (i.e. alpha=0.05,N=21 per group). All surgeries will be performed with a 550 μm fiber. At the start of each case, a laser technician would be notified of randomization via envelope and randomize the settings to either Moses or traditional mode. The surgeons and patients were blinded to which mode was used. All surgeries will be performed using a two lobe technique and laser settings between 2J and 20-40Hz. Further recorded endpoints include change in blood loss, reduction in International Prostate Symptom Score (IPSS), improvement in uroflow parameters, and complications postoperatively at 6 weeks.

Eligibility criteria: Inclusion Criteria:

* Any man with clinical symptoms fo BPH requiring surgery who has a prostate sized at greater than 80 grams

Exclusion Criteria:

* Anyone actively on anticoagulation perioperatively

Primary outcomes:
measure: Operative Time
timeFrame: intraoperatively
Secondary outcomes:
measure: Percentage of Change of Hematocrit
timeFrame: Baseline to postoperatively day 1
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
References:
Clinical trial NCT02856087: The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study
Official title: The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: acute pain
postoperative
surgery
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-08-04
Enrollment: 92
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: High-dose remifentanil infused intraoperative ironically results in postoperative hyperalgesia. Ultra-low dose nalxone is demonstrated to prevent these opioid-induced hyperalgesia in animal model. In this clinical trial in patients undergoing general anesthesia with remifentanil, we evaluate the effects of ultra-low-dose naloxone on remifentanil-induced hyperalgesia

Detailed description: We enrolled adult patients undergoing thyroidectomy under general anesthesia with desflurane and remifentanil. Remifentanil was administered via target-controlled infusion and anesthetic depth was maintained keeping the BIS between 40 and 60. Patients were randomized into one of three groups depending on intraoperative doses of remifentanil and naloxone: effect-site concentrations of remifentanil 1 ng/ml (control group), 4 ng/ml (remifentanil group), and 4 ng/ml combined with infusion rate 0.8 ng/kg/min of naloxone (remifentanil and naloxone group). Postoperative mechanical pain thresholds, pain intensity, and analgesic consumption were examined during 48 h of postoperative period. The primary outcome was mechanical pain threshold measured on the peri-incisional area 24 h after surgery.

Eligibility criteria: Inclusion Criteria:

* patients who are scheduled to undergo elective thyroidectomy

Exclusion Criteria:

* consent refusal, obesity, pregnancy, hx. of thyroid surgery, neurological disorders, psychiatric disorders, hx. of drug abuse or chronic use of opioids or sedative drugs, intake of any analgesic drug within 12h before surgery.

Primary outcomes:
measure: Mechanical pain thresholds
timeFrame: 24hr after surgery
Secondary outcomes:
measure: Mechanical pain thresholds
timeFrame: 48hr after surgery
measure: pain score
timeFrame: verbal numerical rating scale at 24 hr after surgery
measure: pain score
timeFrame: verbal numerical rating scale at 48 after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Yunseok Jeon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Koo CH, Yoon S, Kim BR, Cho YJ, Kim TK, Jeon Y, Seo JH. Intraoperative naloxone reduces remifentanil-induced postoperative hyperalgesia but not pain: a randomized controlled trial. Br J Anaesth. 2017 Dec 1;119(6):1161-1168. doi: 10.1093/bja/aex253.
Clinical trial NCT04672187: Associations of Pre- and Intraoperative Endoscopic Findings of Middle Ear Status in Cholesteatoma
Official title: Middle Ear Status in Cholesteatoma: the Associations of Preoperative Computed Tomography Scans, Audiologic Assessment, and Intraoperative Endoscopic Findings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Middle Ear Cholesteatoma
Keywords: endoscopic,cholesteatoma,audiogram, air-bone gap
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 41
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We prospectively evaluated the preoperative HRCT scanning of the temporal bone and preoperative audiologic assessment compared with an intraoperative endoscopic finding of patients who were diagnosed with chronic otitis media with cholesteatoma and scheduled to a primary surgery at Otolaryngology department, Songklanagarind hospital, Prince of Songkla University between November 2017 to November 2019.

Brief summary: The aim of this study is to assess the accuracy of preoperative HRCT of the temporal bone combined with the preoperative audiologic assessment compared with the intraoperative endoscopic middle ear finding.

Detailed description: The information of the preoperative HRCT scanning of the middle ear cavity in cholesteatoma combined with the preoperative audiologic assessment could be informed the intraoperative middle ear finding in the patients who were diagnosed with chronic otitis media with cholesteatoma, which influence the plan of surgical management. Whether these preoperative assessments can predict the intraoperative finding is unclear. The aim of this study is to assess the accuracy of preoperative HRCT of the temporal bone combined with the preoperative audiologic assessment compared with the intraoperative endoscopic middle ear finding.

Eligibility criteria: Inclusion Criteria:

* The patients included in this study had otorrhea, hearing loss, or aural fullness that last more than 3 months. Otological examination revealed tympanic membrane perforation or retraction, along with cholesteatoma.

Exclusion Criteria:

* Patients who had a previous temporal bone fracture, concomitant with congenital craniofacial anomalies, or underwent previous otologic surgery were excluded.

Primary outcomes:
measure: predictive factor of intraoperative endoscopic finding from preoperative ct finding and preoperative audiological assessment
timeFrame: 2 years
Secondary outcomes:
measure: accuracy between preoperative ct finding and intraoperative endoscopic finding
timeFrame: 2 years
Other outcomes:
Locations:
city: Hat Yai
country: Thailand
facility: Faculty of Medicine, Prince of Songkla University
state: Songkhla
Study officials:
affiliation: Faculty of Medicine, Prince of Songkla University
name: Yuvatiya Plodpai, MD
role: PRINCIPAL_INVESTIGATOR
References: